| Aria Of Brookfield | |
| 18740 W Bluemound Rd, Brookfield, Wisconsin 53045 | |
| (262) 782-0230 | |
| Name | Aria Of Brookfield |
|---|---|
| Location | 18740 W Bluemound Rd, Brookfield, Wisconsin |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 170 |
| Occupancy Rate | 69.47% |
| Medicare ID (CCN) | 525424 |
| Legal Business Name | Legal Business Name Not Available |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1487609178 |
| Organization Name | FIVE STAR QUALITY CARE WI LLC |
| Doing Business As | BROOKFIELD REHABILITATION AND SPECIALTY CARE CENTER |
| Address | 18740 West Bluemound Road, Brookfield, WI 53045 |
| Phone Number | 262-782-0230 |
News Archive
Nearly 3.3 billion people, a little less than half of our world's population, are at risk of malaria, TB and what we call "neglected tropical diseases"—diseases caused by worms, parasites, viruses and bacteria like Chagas disease, river blindness, elephantiasis, sleeping sickness, etc.
Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.
Recent research has shown that cancer cells have a much different - and more complex - metabolism than normal cells. Now, scientists at The University of Texas at Dallas have found that exploiting these differences might provide a new strategy to combat lung cancer.
Cephalon, Inc. announced that it has today completed its previously announced acquisition of Mepha, the Swiss-based pharmaceutical company. As a result of the acquisition, Mepha is now a wholly-owned subsidiary of Cephalon. The purchase price paid at closing, inclusive of certain closing adjustments, was CHF 662.4 million (or approximately US$615.4 million). The purchase price is also subject to further post-closing working capital and net debt adjustments.
Noting the progress made since the beginning of the HIV/AIDS epidemic and the upcoming recognition of World AIDS Day on December 1, Ronald Valdiserri, deputy assistant secretary for health, infectious diseases at the Department of Health and Human Services, writes in a Public Health Reports opinion piece, "We would do well to keep in mind the following caution. No matter the elegance of the controlled trial, the statistical significance of the results, or the superiority of the science, we must confront this inevitable reality: We will never be able to take full advantage of our progress in HIV clinical and prevention science until we develop and sustain the human, organizational, and structural capacities necessary to implement these new scientific breakthroughs."
› Verified 2 days ago
| NPI Number | 1518517424 |
| Organization Name | SNH WIS TENANT LLC |
| Address | 18740 W Bluemound Rd, Brookfield, WI 53045 |
| Phone Number | 262-782-0230 |
News Archive
Nearly 3.3 billion people, a little less than half of our world's population, are at risk of malaria, TB and what we call "neglected tropical diseases"—diseases caused by worms, parasites, viruses and bacteria like Chagas disease, river blindness, elephantiasis, sleeping sickness, etc.
Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.
Recent research has shown that cancer cells have a much different - and more complex - metabolism than normal cells. Now, scientists at The University of Texas at Dallas have found that exploiting these differences might provide a new strategy to combat lung cancer.
Cephalon, Inc. announced that it has today completed its previously announced acquisition of Mepha, the Swiss-based pharmaceutical company. As a result of the acquisition, Mepha is now a wholly-owned subsidiary of Cephalon. The purchase price paid at closing, inclusive of certain closing adjustments, was CHF 662.4 million (or approximately US$615.4 million). The purchase price is also subject to further post-closing working capital and net debt adjustments.
Noting the progress made since the beginning of the HIV/AIDS epidemic and the upcoming recognition of World AIDS Day on December 1, Ronald Valdiserri, deputy assistant secretary for health, infectious diseases at the Department of Health and Human Services, writes in a Public Health Reports opinion piece, "We would do well to keep in mind the following caution. No matter the elegance of the controlled trial, the statistical significance of the results, or the superiority of the science, we must confront this inevitable reality: We will never be able to take full advantage of our progress in HIV clinical and prevention science until we develop and sustain the human, organizational, and structural capacities necessary to implement these new scientific breakthroughs."
› Verified 2 days ago
| NPI Number | 1902407356 |
| Organization Name | ARIA OF BROOKFIELD LLC |
| Address | 18740 W Bluemound Rd, Brookfield, WI 53045 |
| Phone Number | 262-782-0230 |
News Archive
Nearly 3.3 billion people, a little less than half of our world's population, are at risk of malaria, TB and what we call "neglected tropical diseases"—diseases caused by worms, parasites, viruses and bacteria like Chagas disease, river blindness, elephantiasis, sleeping sickness, etc.
Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.
Recent research has shown that cancer cells have a much different - and more complex - metabolism than normal cells. Now, scientists at The University of Texas at Dallas have found that exploiting these differences might provide a new strategy to combat lung cancer.
Cephalon, Inc. announced that it has today completed its previously announced acquisition of Mepha, the Swiss-based pharmaceutical company. As a result of the acquisition, Mepha is now a wholly-owned subsidiary of Cephalon. The purchase price paid at closing, inclusive of certain closing adjustments, was CHF 662.4 million (or approximately US$615.4 million). The purchase price is also subject to further post-closing working capital and net debt adjustments.
Noting the progress made since the beginning of the HIV/AIDS epidemic and the upcoming recognition of World AIDS Day on December 1, Ronald Valdiserri, deputy assistant secretary for health, infectious diseases at the Department of Health and Human Services, writes in a Public Health Reports opinion piece, "We would do well to keep in mind the following caution. No matter the elegance of the controlled trial, the statistical significance of the results, or the superiority of the science, we must confront this inevitable reality: We will never be able to take full advantage of our progress in HIV clinical and prevention science until we develop and sustain the human, organizational, and structural capacities necessary to implement these new scientific breakthroughs."
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Nearly 3.3 billion people, a little less than half of our world's population, are at risk of malaria, TB and what we call "neglected tropical diseases"—diseases caused by worms, parasites, viruses and bacteria like Chagas disease, river blindness, elephantiasis, sleeping sickness, etc.
Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.
Recent research has shown that cancer cells have a much different - and more complex - metabolism than normal cells. Now, scientists at The University of Texas at Dallas have found that exploiting these differences might provide a new strategy to combat lung cancer.
Cephalon, Inc. announced that it has today completed its previously announced acquisition of Mepha, the Swiss-based pharmaceutical company. As a result of the acquisition, Mepha is now a wholly-owned subsidiary of Cephalon. The purchase price paid at closing, inclusive of certain closing adjustments, was CHF 662.4 million (or approximately US$615.4 million). The purchase price is also subject to further post-closing working capital and net debt adjustments.
Noting the progress made since the beginning of the HIV/AIDS epidemic and the upcoming recognition of World AIDS Day on December 1, Ronald Valdiserri, deputy assistant secretary for health, infectious diseases at the Department of Health and Human Services, writes in a Public Health Reports opinion piece, "We would do well to keep in mind the following caution. No matter the elegance of the controlled trial, the statistical significance of the results, or the superiority of the science, we must confront this inevitable reality: We will never be able to take full advantage of our progress in HIV clinical and prevention science until we develop and sustain the human, organizational, and structural capacities necessary to implement these new scientific breakthroughs."
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $650 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 15.87 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 6.79 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 51.43 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.44 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.09 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 4.26 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.52 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.99 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 5.04 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 92.82 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.55 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 39.81 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 15.04 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 9.32 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.46 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 65.78 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 92.21 | 82.93 |
News Archive
Nearly 3.3 billion people, a little less than half of our world's population, are at risk of malaria, TB and what we call "neglected tropical diseases"—diseases caused by worms, parasites, viruses and bacteria like Chagas disease, river blindness, elephantiasis, sleeping sickness, etc.
Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.
Recent research has shown that cancer cells have a much different - and more complex - metabolism than normal cells. Now, scientists at The University of Texas at Dallas have found that exploiting these differences might provide a new strategy to combat lung cancer.
Cephalon, Inc. announced that it has today completed its previously announced acquisition of Mepha, the Swiss-based pharmaceutical company. As a result of the acquisition, Mepha is now a wholly-owned subsidiary of Cephalon. The purchase price paid at closing, inclusive of certain closing adjustments, was CHF 662.4 million (or approximately US$615.4 million). The purchase price is also subject to further post-closing working capital and net debt adjustments.
Noting the progress made since the beginning of the HIV/AIDS epidemic and the upcoming recognition of World AIDS Day on December 1, Ronald Valdiserri, deputy assistant secretary for health, infectious diseases at the Department of Health and Human Services, writes in a Public Health Reports opinion piece, "We would do well to keep in mind the following caution. No matter the elegance of the controlled trial, the statistical significance of the results, or the superiority of the science, we must confront this inevitable reality: We will never be able to take full advantage of our progress in HIV clinical and prevention science until we develop and sustain the human, organizational, and structural capacities necessary to implement these new scientific breakthroughs."
› Verified 2 days ago
Congregational Home, Inc Location: 13900 W Burleigh Rd, Brookfield, Wisconsin 53005 Phone: (262) 781-0550 |